Efruxifermin, an experimental drug mimicking fibroblast growth factor 21 (FGF21), is being investigated in phase 3 SYNCHRONY trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The drug aims to target metabolic pathways to reverse liver scarring without worsening the condition. The SYNCHRONY trials evaluate efruxifermin’s safety and efficacy across various MASH fibrosis stages, including pre-cirrhotic and cirrhotic conditions. Previous phase 2b trials, like the HARMONY trial, demonstrated that efruxifermin effectively improved fibrosis in patients with pre-cirrhotic MASH without worsening the condition, with up to 75% of patients showing at least a 1-stage improvement in fibrosis.

Efruxifermin is being tested in three phase 3 SYNCHRONY trials, which include biopsy-confirmed pre-cirrhotic MASH (SYNCHRONY Histology), non-invasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (SYNCHRONY Real-World), and compensated cirrhosis due to MASH (SYNCHRONY Outcomes). Early trials have shown promising results, with efruxifermin improving fibrosis in patients, particularly at higher doses, while being generally well-tolerated. These findings suggest that efruxifermin has significant potential in treating MASH and could reduce healthcare costs by potentially minimizing the need for liver biopsies.

Reference: McGovern G. Efruxifermin Demonstrates Potential in Treating Patients With MASH-Related Scarring or Cirrhosis. Pharmacy Times. Published February 5, 2025. Accessed March 18, 2025. https://www.pharmacytimes.com/view/efruxifermin-demonstrates-potential-in-treating-patients-with-mash-related-scarring-or-cirrhosis